PXL-770 is under clinical development by Poxel and currently in Phase I for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)). According to GlobalData, Phase I drugs for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PXL-770’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PXL-770 is under development for the treatment of non-alcoholic steatohepatitis (NASH), non alcoholic fatty liver disease,adrenomyeloneuropathy (AMN) form of X-linked adrenoleukodystrophy (X-ALD or ALD), diabetic nephropathy, polycystic kidney disease and diastolic cardiac dysfunction. The drug candidate is administered orally in the form of capsule. It is a new chemical entity. It acts by targeting adenosine monophosphate-activated protein kinase (AMPK). It was also under development for the treatment of type II diabetes and obesity.
Poxel is a biopharmaceutical company. It focuses on to develop drugs for metabolic diseases. The company’s pipeline product portfolio includes Imeglimin, which is developed to target mitochondrial dysfunction, for the treatment of type 2 diabetes; PXL065, a mitochondrial pyruvate carrier, and PXL770, an adenosine monophosphate-activated protein kinase, for non-alcoholic steatohepatitis (NASH) and metabolic diseases; and PXL007, for hepatitis B. Poxel is also developing earlier-stage programs, which includes deuterated drug candidates for the treatment of metabolic, specialty and rare diseases. It works in partnership with Sumitomo Dainippon Pharma, DeuteRx LLC and Roivant Sciences to research and develop products for metabolic disorders. The company is a spin-off from Merck Serono. Poxel is headquartered in Lyon, France.
For a complete picture of PXL-770’s drug-specific PTSR and LoA scores, buy the report here.